Biotech

Biotech

No surprises: FDA rejects Y-mAbs' rare pediatric cancer drug

Weeks after its advisory committee rejected the asset, the FDA hit YmAbs with a CRL and discussed the need for an adequate and well-controlled trial.
Nick Paul Taylor Dec 2, 2022 5:43am

Theratechnologies halts lead cancer trial over efficacy concerns

Dec 2, 2022 5:35am

The future of Alzheimer’s disease research needs solutions

Nov 28, 2022 8:00am

Roche thins Alzheimer’s program after phase 3 failure

Dec 1, 2022 12:52pm
image-icon

The importance of a fully enabled clinical supply platform

Nov 28, 2022 8:00am

SQZ, Synlogic pulled into biotech’s layoff sinkhole

Dec 1, 2022 11:34am